30 years of preventive studies of uterine cervical cancer 1982–2012

The studies for the prevention of uterine cervical cancer in Panama City began in a private institute, impelled by the high incidence of cancer. The preventive programs were initiated with the support of the Obstetrics and Gynecology Institute of the University of Padua n Italy. In these studies, we applied the methodological diagnostics of this Institute with certain modifications adapted to our needs. The diagnosis, treatment, and follow-up were carried out under the protocol of the University of Padua. We achieved a diagnosis of oncogenic isk (OR) in 6,411 patients which corresponded to 5,498 cases of human papillomavirus (HPV), 1,150 cases of dysplasia, 210 cases of cancer, and 794 cases of OR. From 2011, polymerase chain reaction (PCR) was also applied with the aim to improve the accuracy f the diagnosis. With this method the prevalence of pathologies were HPV infections both in healthy patients or in patients cured from PV. Patients were treated by means of local destructive treatments (LDT), basically with cryotherapy and cauterization. We can consider hese results as successful prevention and suggest to extend a preventive program to all the population.

Oncogenic risk prevention; Cervical cancer: Treatment evolution.

[1] Armstrong E.P.: “Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types". J. Manag. Care Pharm., 16, 217.

[2] World Health Organization: “Fact sheet No. 297: Cancer”. Geneva, updated 2014. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/

[3] “GLOBOCAN 2002 database: summary table by cancer”. Available at: http://globocan.iarc.fr/Default.aspx

[4] Kent A.: “HPV vaccination and testing”. Rev. Obstet. Gynecol., 2010, 3, 33.

[5] “NCCC National Cervical Cancer Coalition”. Available at: http://web.archive.org/web/20080822004150/http://www.nccc-online.org

[6] Lozano R.: “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet, 2012, 380, 2095.

[7] Canavan T.P., Doshi N.R.: “Cervical cancer”. Am. Fam. Physician, 2000, 61, 1369.

[8] Gadducci A., Barsotti C., Cosio S.; Domenici L.; Riccardo Genazzani A.: “Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: A review of the literature”. Gynecol. Endocrinol., 2011, 27, 597. doi:10.3109/09513590.2011.558953

[9] Campbell S., Monga A.: “Gynaecology by Ten Teachers”. 18th ed. London: Hodder Education, 2006.

[10] Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al.: “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide”. J. Pathol., 1999, 189, 12.

[11] Garrido J.L.: “Apporte dela colposcopia di fronte all infezione del HPV puro ed associato alle displasie e cancro”. Congresso LXIX SIGO 1993, 562.

[12] Garrido J.L.: “Screening of cervical cancer: 27 years experience in six Republics of Panama”. Clin. Exp. Obstet. Gynecol., 2012, 39, 343.

[13] Garrido J.L.: “Incidencia patológica de pacientes primerizas al estudio colpo-citológico 1984-1986”. Ginecologia clínica, 1989, 10, 111.

[14] Dexeus S. “CIN Treatments”. Eur. J. Gynaecol. Oncol., 1989, 20, 285.

[15] Machado F.A., Janssens J.P., Michelin M.A., Murta E.F. “Immune response and immunotherapy in intraepithelial and invasive lesions of the uterine cervix”. Clin. Exp. Obstet. Gynecol., 2012, 39, 27.

[16] Michelin M.A., Murta E.F.: “Potential therapeutic vaccine strategic and relevance of the immune system in uterine cervical cancer”. Eur. J. Gynaecol. Oncol., 2008, 29, 10.

[17] Deligeoroglou E., Christopoulos P., Aravantinos L., Papadias K. “Human papilloma virus molecular profile and mechanisms of cancerogenesis: a review”. Eur. J. Gynaecol. Oncol., 2009, 30, 128.

[18] Agnantis N.J., Sotiriadis A., Paraskevaidis E.: “The current status of HPV DNA testing”. Eur. J. Gynaecol. Oncol., 2003, 24, 351.

[19] Christopoulos P., Papadias K., Panoulis K., Deligeoroglou E.: “Human papillomavirus in adolescence”. Clin. Exp. Obstet. Gynecol., 2009, 35, 248

[20] Garrido J.L.: “Comparative findings of oncogenic cervical risk and its follow-up in two different periods 1982-1999 and 2000-2010”. Eur. J. Gynaecol. Oncol., 2010, 31, 559.

[21] Tuncer Z.S., Boyraz G., Sahin N., Alp A.: “Distribution of human papillomavirus types in Turkish women”. Eur. J. Gynaecol. Oncol., 2012, 33, 204.

[22] Brinkman J.A., Caffrey A.S., Muderspach L.I., Roman L.D., Kast W.M.: “The impact of anti HPV vaccination on cervical cancer: consequences for clinical management”. Eur. J. Gynaecol. Oncol., 2005, 26, 129.

[23] Szarewski A.: “Prophylactic HPV vaccines”. Eur. Gynaecol. Oncol., 2007, 38, 165.

[24] Syrjanen K.: “Persistent high risk human papillomavirus HPV infections as surrogate endpoints of progressive cervical disease. Potential new endpoint for efficacy studies with new-generation non 16/18 prophylactic HPV vaccines”. Eur. J. Gynaecol. Oncol., 2011, 32, 17.